Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 13/20 | 0.49 |
| ▸ | CA1 | P00915 | 12/20 | 0.49 |
| ▸ | CA12 | O43570 | 10/20 | 0.48 |
| ▸ | CA4 | P22748 | 8/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5398932 | 0.91 | CA2 (0.49) | CA2CA1CA12CA4HSD17B10 | |
| SCHEMBL5401053 | 0.91 | CA2 (0.55) | CA2CA1CA12CA4HSD17B10 | |
| SCHEMBL5403753 | 0.91 | ALDH1A1 (0.53) | HSD17B10KDM4EALDH1A1HPGDMEN1 | |
| SCHEMBL5413978 | 0.90 | ALDH1A1 (0.50) | HSD17B10KDM4EALDH1A1HPGDMEN1 | |
| SCHEMBL5403070 | 0.90 | CA2 (0.49) | CA2CA1CA12CA4KMT2A | |
| SCHEMBL5401176 | 0.90 | CA1 (0.49) | CA2CA1CA12CA4HSD17B10 | |
| SCHEMBL5394590 | 0.89 | RAB9A (0.57) | CA2CA1CA12CA4KDM4E | |
| SCHEMBL5402281 | 0.86 | HPGD (0.52) | HSD17B10KDM4EALDH1A1HPGDMEN1 | |
| SCHEMBL5414032 | 0.86 | CA2 (0.49) | CA2CA1CA12CA4HSD17B10 | |
| SCHEMBL5392449 | 0.86 | CA2 (0.53) | CA2CA1CA12CA4HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7285680-B2 | β-alanine derivatives and the use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-10-23 | — | — | US | disclosed |
| US-20050256160-A1 | Beta-alanine derivatives and the use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-11-17 | — | — | US | disclosed |
| EP-1533294-A1 | BETA-ALANINE DERIVATIVE AND USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-05-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050256160-A1 | Beta-alanine derivatives and the use thereof | TGFB1, PML, APOB | CA2 1987/4885CA1 722/4885CA12 1604/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.